DBVT vs. IVVD, CHRS, GLUE, ELEV, ZURA, SCLX, CRBU, INMB, FENC, and CGEN
Should you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include Invivyd (IVVD), Coherus BioSciences (CHRS), Monte Rosa Therapeutics (GLUE), Elevation Oncology (ELEV), Zura Bio (ZURA), Scilex (SCLX), Caribou Biosciences (CRBU), INmune Bio (INMB), Fennec Pharmaceuticals (FENC), and Compugen (CGEN). These companies are all part of the "biological products, except diagnostic" industry.
DBV Technologies (NASDAQ:DBVT) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.
DBV Technologies received 391 more outperform votes than Invivyd when rated by MarketBeat users. However, 66.67% of users gave Invivyd an outperform vote while only 56.84% of users gave DBV Technologies an outperform vote.
Invivyd has a net margin of 0.00% compared to DBV Technologies' net margin of -530.89%. DBV Technologies' return on equity of -56.76% beat Invivyd's return on equity.
DBV Technologies has higher revenue and earnings than Invivyd. DBV Technologies is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.
71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 1.9% of DBV Technologies shares are held by insiders. Comparatively, 17.9% of Invivyd shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, DBV Technologies had 3 more articles in the media than Invivyd. MarketBeat recorded 4 mentions for DBV Technologies and 1 mentions for Invivyd. Invivyd's average media sentiment score of 0.92 beat DBV Technologies' score of 0.26 indicating that Invivyd is being referred to more favorably in the news media.
DBV Technologies currently has a consensus target price of $6.67, suggesting a potential upside of 547.25%. Invivyd has a consensus target price of $11.33, suggesting a potential upside of 531.38%. Given DBV Technologies' higher probable upside, equities analysts plainly believe DBV Technologies is more favorable than Invivyd.
DBV Technologies has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.
Summary
DBV Technologies beats Invivyd on 9 of the 17 factors compared between the two stocks.
Get DBV Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DBV Technologies Competitors List
Related Companies and Tools
